Abstracts tagged "Biologic drugs"

Abstract Number: 2078 • 2018 ACR/ARHP Annual Meeting
Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy
Patricia Ruiz-Limon¹, M. Carmen Castro-Villegas², Chary Lopez-Pedrera³, Rafaela Ortega-Castro⁴, Maria Carmen Abalos-Aguilera¹, Nuria Barbarroja⁴, Carlos Perez-Sanchez⁴, Ivan Arias de la Rosa¹, Alejandro Ibáñez-Costa³, Alejandra Maria Patiño-Trives³, Daniel Espejo-Peralbo¹, Pilar Font-Ugalde⁴, Jose Antonio Gonzalez-Reyes⁵, Jose Manuel Villalba⁵, Clementina López-Medina⁴, Alejandro Escudero-Contreras¹, Eduardo Collantes-Estévez⁴ and Yolanda Jiménez-Gómez⁴, ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain
Background/Purpose: NETosis has been suggested to play a central role in several rheumatology diseases. Nevertheless, this process, and its modulation in therapeutic response has not…
Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Daeria O. Lawson^1,2, Maria Eraso³, Lawrence Mbuagbaw⁴, Theresa Aves⁵, Alvin Leenus⁴, Marianinha Joanes⁶, Ahmed Omar^1,7 and Robert D Inman^8,9, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ⁵St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Boston University School of Medicine, Boston, MA, United States, Boston, MA, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Guro Løvik Goll¹, Nils Bolstad², Ines Iria^3,4, Rolf Klaasen⁵, Kristin Kaasen Jørgensen⁶, Inge C Olsen⁷, Ana Valido⁸, Maria J Saavedra⁹, João E. Fonseca¹⁰, Merete Lorentzen¹¹, Cato Mork¹², Knut EA Lundin¹³, David J Warren¹⁴, Espen A. Haavardsholm¹⁵, Jorgen Jahnsen¹⁶, Tore Kvien¹⁵ and João Gonçalves¹⁷, ¹Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ³Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, ⁴iMed- Research Institute for medicines, Lisbon, Portugal, ⁵Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ⁶Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹¹Dept of Dermatology, Rikshospitalet, Oslo, Norway, ¹²Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ¹³Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, ¹⁴Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ¹⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ¹⁷Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
Abstract Number: 2385 • 2018 ACR/ARHP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Mary Ellen Riordan⁵, Anne C. Dennos⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Brian M. Feldman⁹ and Yukiko Kimura⁵, ¹Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ²Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Duke University Medical Center, Durham, NC, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Parent Partner, Whitehouse Station, NJ, ⁸Parent Partner, San Francisco, CA, ⁹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: There is significant variation in the timing of when biologic medications are started during initial treatment for polyarticular juvenile idiopathic arthritis (P-JIA) in clinical…
Abstract Number: 703 • 2018 ACR/ARHP Annual Meeting
Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Anastasia Dupré¹, Michael Collins², Franck Carbonnel³, Xavier Mariette^4,5 and Raphaele Seror¹, ¹Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, ²Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-Enterology, Université Paris Sud, Le Kremlin Bicêtre, France, ³Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-enterology, Université Paris Sud, Le Kremlin Bicêtre, France, ⁴Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, ⁵Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France
Background/Purpose: Vedolizumab is a humanised IgG1 monoclonal antibody anti-α4β7 integrin agent used in inflammatory bowel disease (IBD). It modulates gut inflammation by preventing leukocyte migration…
Abstract Number: 2509 • 2018 ACR/ARHP Annual Meeting
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment
Mark C. Genovese¹, Hubert van Hoogstraten², Gregory St. John³, Qunming Dong², Juan José Gómez-Reino⁴, José A. Maldonado-Cocco⁵, Juan Carlos Salazar⁶, Tom W.J. Huizinga⁷ and Gerd R. Burmester⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Sanofi Genzyme, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain, ⁵School of Medicine, Buenos Aires University, Buenos Aires, Argentina, ⁶Riesgo de Fractura S.A - CAYRE, Bogotá, Colombia, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: EXTEND (NCT01146652) is an ongoing open-label extension study enrolling patients completing five sarilumab originator studies (MOBILITY [NCT01061736]; TARGET [NCT01709578]; ASCERTAIN [NCT01768572]; ACT11575 [NCT01217814]; ONE…
Abstract Number: 960 • 2018 ACR/ARHP Annual Meeting
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
Andrei Barbulescu¹, Thomas Frisell¹, Johan Askling² and Bénédicte Delcoigne¹, ¹Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Gastrointestinal (GI) perforations occur more often than expected in patients with RA. Reports indicate that tocilizumab may be associated with an increased risk of…
Abstract Number: 2527 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
Roy Fleischmann¹, Yong Lin², Gregory St. John³, Désirée van der Heijde⁴, Chunfu Qiu², Juan José Gómez-Reino⁵, José A. Maldonado-Cocco⁶, Marina Stanislav⁷, Bruno Seriolo⁸ and Gerd R. Burmester⁹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Sanofi Genzyme, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Leiden University Medical Centre, Leiden, Netherlands, ⁵IDIS, Complejo Hospitalario Universitario de Santiago, Santiago, Spain, ⁶School of Medicine, Buenos Aires University, Buenos Aires, Argentina, ⁷Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, ⁸Department of Internal Medicine, University of Genova, Genova, Italy, ⁹Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Sarilumab has shown efficacy in RA both as monotherapy and in combination with csDMARDs in Phase 3 trials. We assessed long-term safety from the…
Abstract Number: 978 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis
Gerd Horneff¹, Ivan Foeldvari², Ralf Trauzeddel³, Toni Hospach⁴, Kirsten Minden⁵, Hans-Iko Huppertz^6,7 and Ariane Klein⁸, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Hamburger Zentrum fur, Kinder-und Jugendrheumatologie, Hamburg, Germany, ³Helios Clinics, Berlin, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Prof Hess Clinic, Bremen, Germany, ⁷Prof. Hess Childrens Hospital, Bremen, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most prevalent chronic diseases of childhood and adolescence. Evidence suggests that early effective treatment is important…
Abstract Number: 2529 • 2018 ACR/ARHP Annual Meeting
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
John Tesser¹, Gregory St. John², Toshio Kimura², Stefano Fiore³, Maureen Rischmueller⁴, José A. Maldonado-Cocco⁵, Jürgen Braun⁶ and Jeffrey Kaine⁷, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Clinical Science, Sanofi Genzyme, Bridgewater, NJ, ⁴The University of Adelaide, Adelaide, Australia, ⁵Buenos Aires University School of Medicine, Buenos Aires, Argentina, ⁶Ruhr-University Bochum, Bochum, Germany, ⁷Sarasota Arthritis Research Center, Sarasota, FL
Background/Purpose: Sarilumab showed efficacy in RA and superiority to placebo and adalimumab in Phase 3 trials. This post hoc analysis investigated LFT levels in three…
Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 624 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial
Philip S. Helliwell¹, Eric Lespessailles², Catherine Shuler³, Lotus Mallbris³, Janelle Erickson³ and Roy Fleischmann⁴, ¹St. Luke's Hospital and University of Leeds, Bradford, United Kingdom, ²University Orleans, Orleans, France, ³Eli Lilly and Company, Indianapolis, IN, ⁴Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. In the SPIRIT-P1 phase 3 study (NCT01695239), IXE was superior to placebo…
Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Daniel Aletaha¹, Carter Thorne², Michael Schiff³, Masayoshi Harigai⁴, Prasheen Agarwal⁵, Ravi Rao⁶, Christopher Cohen⁷, Ben Cheng⁵, Kurt Brown⁷ and Benjamin Hsu⁵, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²University of Toronto, Newmarket, ON, Canada, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ⁷GlaxoSmithKline, Collegeville, PA
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…
Abstract Number: 628 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
Bernard Combe¹, Peter Nash², David Adams³, Lisa Kerr³ and Olivier Benichou³, ¹Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ²University of Queensland, Brisbane, Australia, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. Here, we present integrated efficacy data at Week 24 from two phase 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].